

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

September 8, 2022

Chordia named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022

Kanagawa, Japan,

September 8, 2022 – Chordia today announced that the company received the “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award”, the most prominent one at Academic Startups 2022. The award was given to Chordia based on the evaluation that it has built a well-developed research and clinical structure with advanced technology and diverse team members, and it is promoting the development of new drugs in wide range of aims and high unmet medical needs, based on alliances with many companies and academia. Chordia will continue its efforts to research and develop first-in-class anti-cancer drugs through collaboration with universities, research institutes, and companies in the healthcare industry, with the aim of creating innovative new drugs.

About the Academic Startups Award

The Award for Academic Startups program has been honoring promising university-oriented startups that are selected from venture businesses that make use of the research developed by universities and other institutions. This program also honors universities, companies and other entities that have made particular contributions to the growth of such startups. This program aims to further promote the establishment of businesses that make use of R&D outcomes achieved by universities or other entities, encourage startups to innovate further, and encourage universities or companies to support university-oriented startups. For more information, please visit the website at <https://www.jst.go.jp/aas/award.html>

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia’s lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan. CTX-712 potentially targets the vulnerability of cancer, and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

info@chorditherapeutics.com



Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact Kentaro Kume, IR: info@chorditherapeutics.com